Doctors appeal to prescribe Avastin off-label
February 25, 2015Sales and Marketing Lucentis, NHS, NICE, Novartis, Roche, bevacizumab, wet AMD
NHS Clinical Commissioners have called for the removal of barriers preventing CCGs from prescribing Roche’s Avastin to treat wet age-related …
FDA in Novartis cancer drug U-turn
February 24, 2015Research and Development, Sales and Marketing Cancer, FDA, Farydak, Novartis, Revlimid, Velcade, myeloma
The FDA has overturned an earlier advisory committee recommendation and decided to approve Novartis’ blood cancer drug Farydak. In November …
Takeda acquires Turkish firm Neutec
February 24, 2015Sales and Marketing Takeda, Turkey, gastroenterology, neutec, respiratory, turkish
Takeda has signed an agreement to acquire one of Turkey’s leading pharma firms Neutec in a $120 million deal. The …
Merck puts HIV drug in shared patent pool
February 24, 2015Research and Development, Sales and Marketing AbbVie, Gilead, HIV, Merck, Raltegravir, Roche, isentress
Merck is teaming up with the Medicines Patent Pool (MPP) to license its paediatric HIV treatment in developing countries. The …
Novel device could help fight kidney disease
February 24, 2015Research and Development, Sales and Marketing Bio Nano Consulting, Pfizer, QELFA, Rapamune, device, ime, kidney
A novel device that combines nanotechnology and a pregnancy tester could help treat kidney disease, according to a report by …
BMS in $1.5 billion immuno-oncology expansion
February 24, 2015Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, Rigel, flexus, immuno-oncology
Bristol-Myers Squibb has confirmed two major deals to enhance the company’s standing in the immuno-oncology field. The first agreement sees …
WuXi PharmaTech borrows to expand
February 24, 2015Manufacturing and Production, Sales and Marketing China, NextCODE Health, WuXi PharmaTech, XenoBiotic Laboratories, philadelphia
WuXi PharmaTech has kick started a syndicated loan arrangement in order to borrow up to $165 million from a consortium …
Algatech gets new chief executive and chief scientist
February 24, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Algatech, Ronnie Meninger, Sammy Boussiba
Israel-based biotech Algatech has confirmed the appointment of Ronnie Meninger as its chief executive, and Sammy Boussiba as chief scientist. Meninger (pictured) …
Merck invests $450m in NGM Biopharma
February 23, 2015Sales and Marketing Merck, NGM Biopharma, NP201, diabetes, nonalcoholic steatohepatitis, obesity
Merck is to collaborate on drug development with biotech firm NGM Pharmaceuticals in a $450 million deal. The collaboration will …
Priority review for Pfizer’s lung drug
February 23, 2015Sales and Marketing FDA, Pfizer, Rapamune, lung, lymphangioleiomyomatosis, sirolimus
The US Food and Drug Administration FDA has accepted Pfizer’s lung drug Rapamune for priority review. Rapamune (sirolimus) prevents organ …
Chiesi’s stem cell therapy approved in Europe
February 23, 2015Research and Development, Sales and Marketing Chiesi, EC, Europe, Holoclar, Holostem Advanced Therapies, LSCD, stem cell
Chiesi’s Holoclar has become the first stem cell therapy to get the green light in Europe, gaining conditional approval from …
UK government spends £300 million on dementia
February 23, 2015Research and Development, Sales and Marketing Cameron, England, NHS, dementia, investment, research
UK prime minister David Cameron has said the government is to invest more than £300m into dementia research and that …
Valeant to buy Salix in $14.5 billion move
February 23, 2015Sales and Marketing Deals, Heptares, Valeant, mergers, salix, sosei
Valeant has agreed a deal to acquire US-based speciality manufacturer of gastrointestinal drugs Salix in a move worth around $14.5 …
Act now – or risk running out of time for IDMP
February 23, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EMA, Eversheds, ISO, icsr, idmp, regulatory
Many people in pharma would argue that the world of regulatory compliance in the life sciences industry is already complicated …
Kymab hires chief financial officer
February 23, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing anne hyland, kymab
Cambridge-based UK antibody development firm Kymab has appointed Anne Hyland as its chief financial officer. Hyland takes to the firm …
Boehringer’s beer breach at German congress
February 20, 2015Medical Communications, Sales and Marketing ABPI, Boehringer, ERS, IPF, PMCPA, breach, code, munich
A complaint made by a pulmonologist against the competence of Boehringer Ingelheim speakers during a congress held in Germany last …
Chair appointed for new MHRA devices committee
February 20, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing MHRA, Peter Nightingale, deac
Dr Peter Nightingale has been appointed as chairman of the Medicines and Healthcare products Regulatory Agency’s (MHRA) newly-formed Devices Expert …
Resistance threat to malaria drug is ‘alarming’
February 20, 2015Research and Development, Sales and Marketing Africa, Qinghaosu, artemisinin, malaria, thailand
Resistance to a group of drugs that possess the most rapid action against malaria – artemisinin, aka Qinghaosu – is …
Official linked to GSK bribes facing prison
February 20, 2015Sales and Marketing China, Deirdre Connelly, GSK, Jack Bailey, Novartis, bribes
A Chinese health official linked to the GSK bribery scandal has been sentenced to 19 years in prison. Huang Fenping, …
Sanofi confirms new chief executive
February 20, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Chris Viehbacher, Sanofi, praluent
Bayer chairman Olivier Brandicourt has been named as Sanofi’s new chief executive to replace Chris Viehbacher who was ejected from …
Latest content
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
